Sandra P. D'Angelo
Cited by
Cited by
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia, P Terheyden, SP D'Angelo, ...
The lancet oncology 17 (10), 1374-1385, 2016
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at …
TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ...
Journal of Clinical Oncology 33 (28), 3193, 2015
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ...
The Lancet Oncology 18 (11), 1493-1501, 2017
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersMolecular Epidemiology of …
S Dogan, R Shen, DC Ang, ML Johnson, SP D'Angelo, PK Paik, ...
Clinical cancer research 18 (22), 6169-6177, 2012
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
SP D'Angelo, MR Mahoney, BA Van Tine, J Atkins, MM Milhem, ...
The Lancet Oncology 19 (3), 416-426, 2018
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label …
J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ...
Journal of clinical oncology 36 (4), 383, 2018
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
MA Dickson, WD Tap, ML Keohan, SP D'Angelo, MM Gounder, ...
Journal of clinical oncology 31 (16), 2024-2028, 2013
Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D’Angelo, J Russell, C Lebbé, B Chmielowski, T Gambichler, JJ Grob, ...
JAMA oncology 4 (9), e180077-e180077, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
HL Kaufman, JS Russell, O Hamid, S Bhatia, P Terheyden, SP D’Angelo, ...
Journal for immunotherapy of cancer 6, 1-7, 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial SarcomaNY-ESO-1c259T Cells in Synovial Sarcoma
SP D'Angelo, L Melchiori, MS Merchant, D Bernstein, J Glod, R Kaplan, ...
Cancer discovery 8 (8), 944-957, 2018
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas
SP D'Angelo, MC Pietanza, ML Johnson, GJ Riely, VA Miller, CS Sima, ...
Journal of clinical oncology 29 (15), 2066, 2011
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
SP D’Angelo, AN Shoushtari, NP Agaram, D Kuk, LX Qin, RD Carvajal, ...
Human pathology 46 (3), 357-365, 2015
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Bullous Pemphigoid with Anti–PD-1/PD-L1 Therapy
J Naidoo, K Schindler, C Querfeld, K Busam, J Cunningham, DB Page, ...
Cancer immunology research 4 (5), 383-389, 2016
Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial
MA Dickson, GK Schwartz, ML Keohan, SP D’Angelo, MM Gounder, P Chi, ...
JAMA oncology 2 (7), 937-940, 2016
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
SP D’Angelo, YY Janjigian, N Ahye, GJ Riely, JE Chaft, CS Sima, R Shen, ...
Journal of Thoracic Oncology 7 (12), 1815-1822, 2012
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan …
JJ Luke, MK Callahan, MA Postow, E Romano, N Ramaiya, M Bluth, ...
Cancer 119 (20), 3687-3695, 2013
Ipilimumab for patients with advanced mucosal melanoma
MA Postow, JJ Luke, MJ Bluth, N Ramaiya, KS Panageas, DP Lawrence, ...
The oncologist 18 (6), 726-732, 2013
The system can't perform the operation now. Try again later.
Articles 1–20